Prostacyclin prevents ischemia-induced increase of lactate and cyclic AMP in ischemic myocardium.
The effect of prostacyclin (PGI2, 0.5 nmol . kg-1 . min-1,i.v.) on myocardial metabolism was studied in cats subjected to 5 h of myocardial ischemia (MI) and compared to vehicle-treated MI cats. MI was followed by a 52% decrease in ATP and a concomitant increase (2-3 fold) in lactate and lactate/pyruvate ratio in the severely ischemic area. PGI2 prevented this increase in lactate with an unchanged ATP and lactate/pyruvate ratio. Moreover, PGI2 abolished the ischemia-induced in myocardial cAMP. It is concluded, the PGI2 exerts its beneficial actions on ischemic myocardium partly via cAMP-linked mechanisms.
D000818:Animals; D002415:Cats; D003327:Coronary Disease / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D004734:Energy Metabolism / Q000187:drug effects; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D007773:Lactates / Q000378:metabolism*; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D011453:Prostaglandins / Q000494:pharmacology*
D007773:Lactates; D011453:Prostaglandins; D011464:Epoprostenol; D000242:Cyclic AMP